Dermira Inc (NASDAQ:DERM) – Equities researchers at Cantor Fitzgerald dropped their FY2018 EPS estimates for shares of Dermira in a note issued to investors on Tuesday, Zacks Investment Research reports. Cantor Fitzgerald analyst L. Chen now expects that the biopharmaceutical company will post earnings per share of ($4.49) for the year, down from their prior forecast of ($3.71). Cantor Fitzgerald currently has a “Buy” rating and a $20.00 target price on the stock.
DERM has been the subject of a number of other research reports. Zacks Investment Research lowered Dermira from a “hold” rating to a “sell” rating in a research note on Thursday, March 8th. Mizuho lowered Dermira from a “buy” rating to a “neutral” rating in a research note on Monday, March 5th. BidaskClub upgraded Dermira from a “hold” rating to a “buy” rating in a research report on Tuesday, January 30th. Guggenheim assumed coverage on Dermira in a research report on Tuesday, December 5th. They issued a “buy” rating for the company. Finally, Leerink Swann lifted their target price on Dermira from $42.00 to $48.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 17th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $32.71.
NASDAQ DERM traded down $0.33 during mid-day trading on Friday, reaching $7.66. 1,254,700 shares of the company’s stock traded hands, compared to its average volume of 1,599,924. Dermira has a 1-year low of $7.53 and a 1-year high of $35.76. The company has a quick ratio of 5.28, a current ratio of 5.28 and a debt-to-equity ratio of 1.87. The firm has a market cap of $334.16, a PE ratio of -1.74 and a beta of 1.54.
Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.09). Dermira had a negative net margin of 6,678.29% and a negative return on equity of 62.07%. The business had revenue of $1.34 million for the quarter, compared to analyst estimates of $1.10 million.
In related news, SVP Christopher M. Griffith sold 18,458 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $27.05, for a total transaction of $499,288.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.07, for a total value of $81,210.00. Following the transaction, the insider now owns 5,802 shares of the company’s stock, valued at approximately $157,060.14. The disclosure for this sale can be found here. In the last quarter, insiders sold 26,758 shares of company stock valued at $728,459. Insiders own 13.30% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC boosted its position in Dermira by 0.3% during the 3rd quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock valued at $71,300,000 after purchasing an additional 7,746 shares during the period. Millennium Management LLC acquired a new position in Dermira during the 4th quarter valued at approximately $25,084,000. Franklin Resources Inc. acquired a new position in Dermira during the 4th quarter valued at approximately $24,820,000. State Street Corp boosted its position in Dermira by 38.4% during the 2nd quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock valued at $23,946,000 after purchasing an additional 228,093 shares during the period. Finally, Point72 Asset Management L.P. boosted its position in Dermira by 621.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 712,904 shares of the biopharmaceutical company’s stock valued at $19,248,000 after purchasing an additional 614,138 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.